Carra; Ernest A.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Carra; Ernest A..The latest application filed is for "crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate".

Company Profile

7.11.13

Carra; Ernest A. - Foster City CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Crystalline forms of (2R,5S,13aR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-1- 0-carboxamide Grant 11,202,780 - Carra , et al. December 21, 2	2021-12-21
Crystalline Forms Of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) Phosphoryl)amino)propanoate App 20210163523 - Brak; Katrien ; et al.	2021-06-03
Solid forms of an ASK1 inhibitor Grant 10,946,004 - Andres , et al. March 16, 2	2021-03-16
Crystalline Forms Of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-1- 0-carboxamide App 20200390775 - Carra; Ernest A. ; et al.	2020-12-17
Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(p- henoxy) phosphoryl)amino)propanoate Grant 10,836,787 - Brak , et al. November 17, 2	2020-11-17
N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide Grant RE48,285 - Brown , et al. October 27, 2	2020-10-27
Solid Forms Of An Ask1 Inhibitor App 20200061042 - Andres; Mark ; et al.	2020-02-27
Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,- 5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxa- zepin-8-olate Grant 10,385,067 - Carra , et al. A	2019-08-20
Crystalline Forms Of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-1- 0-carboxamide App 20190015420 - Carra; Ernest A. ; et al.	2019-01-17
Crystalline Forms Of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) Phosphoryl)amino)propanoate App 20180346504 - Brak; Katrien ; et al.	2018-12-06
Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13A- octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-B] [1,3] oxazepine-10-carboxamide Grant 10,098,886 - Carra , et al. October 16, 2	2018-10-16
Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,- 5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxa- Zepin-8-olate App 20180065986 - CARRA; ERNEST A. ; et al.	2018-03-08
Crystalline Forms Of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-1- 0-carboxamide App 20170333438 - Carra; Ernest A. ; et al.	2017-11-23
(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide Grant 9,809,559 - Brown , et al. November 7, 2	2017-11-07
Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,- 5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate Grant 9,708,342 - Carra , et al. July 18, 2	2017-07-18
Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,- 5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxa- Zepin-8-olate App 20170197985 - Carra; Ernest A. ; et al.	2017-07-13
Crystalline forms of (2R,5S,13AR)-8-hydroxy-7,9,-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,1- 3,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-- 10-carboxamide Grant 9,682,084 - Carra , et al. June 20, 2	2017-06-20
Solid forms of an ASK1 inhibitor Grant 9,643,956 - Andres , et al. May 9, 2	2017-05-09
(n-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide App 20160347719 - Brown; Brandon H. ; et al.	2016-12-01
(N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide Grant 9,469,613 - Brown , et al. October 18, 2	2016-10-18
Solid Forms Of An Ask1 Inhibitor App 20160280683 - Andres; Mark ; et al.	2016-09-29
Sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,- 5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b]oxazepin- -8-olate App 20160016973 - Carra; Ernest A. ; et al.	2016-01-21
Crystalline Forms Of (2r,5s,13ar)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13- ,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-1- 0-carboxamide App 20150366872 - Carra; Ernest A. ; et al.	2015-12-24
(n-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide App 20150361050 - Brown; Brandon H. ; et al.	2015-12-17

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.